openPR Logo
Press release

Onychomycosis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Clinical Trials By DelveInsight | Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, Moberg Pharma, Sato Pharma

07-10-2024 04:48 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Onychomycosis Pipeline Trends 2024: Clinical Trials,

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Onychomycosis pipeline constitutes 11+ key companies continuously working towards developing 11+ Onychomycosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Onychomycosis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Onychomycosis Market.

The Onychomycosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Onychomycosis Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Onychomycosis treatment therapies with a considerable amount of success over the years.

*
Onychomycosis companies working in the treatment market are Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, MediQuest Therapeutics, Polichem S.A, Repolar Ltd., Celtic Pharma, GlaxoSmithKline, Hisamitsu Pharma, Polichem S.A., Pfizer, Bausch Health, Halcygen Pharma, Meiji Seika Pharma, photonamic GmbH, Viamet, Novartis, Topica Pharma, Taro Pharma, NanoBio Crp, Hallux, Inc., Merck Sharp & Dohme, Bayer, Abeona Therapeutics, Dow Pharma, Taro Pharma, and others, are developing therapies for the Onychomycosis treatment

*
Emerging Onychomycosis therapies in the different phases of clinical trials are- MOB-015, BB2603, HSG, Tavaborole, MOB015B, P-3058, Organogel of naftifine, Amorolfine, TDT067 and Lamisil, Albaconazole, HTU-520, P-3058, AN2690, Efinaconazole, SUBA-itraconazole, ME1111, PD P 506 A, VT-1161, terbinafine, Luliconazole, NVXT topical, NB-002, HTS-519, SCH 56592, Bifonazole cream 1%, EcoNail Trademark , IDP-108, Itraconazole, and others are expected to have a significant impact on the Onychomycosis market in the coming years.

*
Acquired by Pfizer, Anacor Pharmaceuticals Inc. has made notable advancements in the treatment of dermatophytic onychomycosis. Their topical antifungal product, Kerydin (tavaborole), is well-regarded for its effectiveness in treating onychomycosis.

*
Johnson & Johnson, via its subsidiary Janssen Pharmaceuticals, plays a significant role in the dermatophytic onychomycosis treatment market. The company's focus on research and development has resulted in the development of effective antifungal treatments. Johnson & Johnson's extensive distribution network and strong brand reputation ensure their treatments are widely accessible.

Onychomycosis Overview

Onychomycosis is a fungal infection that affects the nails, typically the toenails but sometimes the fingernails as well. This condition, also known as tinea unguium, is caused by various types of fungi, including dermatophytes, yeasts, and non-dermatophyte molds.

Get a Free Sample PDF Report to know more about Onychomycosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/onychomycosis-pipeline-insight [https://www.delveinsight.com/report-store/onychomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Onychomycosis Drugs Under Different Phases of Clinical Development Include:

*
MOB-015: Moberg Pharma

*
BB2603: Blueberry Therapeutics

*
HSG: Hallux

*
Tavaborole: Pfizer

*
MOB015B: Moberg Pharma AB

*
P-3058: Polichem S.A.

*
Organogel of naftifine: MediQuest Therapeutics

*
Amorolfine: Repolar Ltd.

*
TDT067 and Lamisil: Celtic Pharma

*
Albaconazole: GlaxoSmithKline

*
HTU-520: Hisamitsu Pharma

*
P-3058: Polichem S.A.

*
AN2690: Pfizer

*
Efinaconazole: Bausch Health

*
SUBA-itraconazole: Halcygen Pharma

*
ME1111: Meiji Seika Pharma

*
PD P 506 A: photonamic GmbH

*
VT-1161: Viamet

*
terbinafine: Novartis

*
Luliconazole: Topica Pharma

*
NVXT topical: Taro Pharma

*
NB-002: NanoBio Crp

*
HTS-519: Hallux, Inc.

*
SCH 56592: Merck Sharp & Dohme

*
Bifonazole cream 1%: Bayer

*
EcoNail Trademark : Abeona Therapeutics

*
IDP-108: Dow Pharma

*
Itraconazole: Taro Pharma

Onychomycosis Route of Administration

Onychomycosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Onychomycosis Molecule Type

Onychomycosis Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Onychomycosis Pipeline Therapeutics Assessment

*
Onychomycosis Assessment by Product Type

*
Onychomycosis By Stage and Product Type

*
Onychomycosis Assessment by Route of Administration

*
Onychomycosis By Stage and Route of Administration

*
Onychomycosis Assessment by Molecule Type

*
Onychomycosis by Stage and Molecule Type

DelveInsight's Onychomycosis Report covers around 11+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Onychomycosis product details are provided in the report. Download the Onychomycosis pipeline report to learn more about the emerging Onychomycosis therapies [https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Onychomycosis Therapeutics Market include:

Key companies developing therapies for Onychomycosis are - Bausch Health Companies, Celtic Pharma, Galderma S.A., Johnson & Johnson, Anacor Pharmaceuticals Inc., Pfizer Inc., GlaxoSmithKline Plc, Novartis AG, Topica Pharmaceuticals Inc., Bayer AG, Moberg Pharma AB, Allergen Inc., Cipla Ltd, Reddy's Laboratories Ltd, Sanofi S.A., Merz Pharma, Medimetriks Pharmaceuticals Inc., NovaBiotics Inc., ZimVie Inc., Wieland Dental, Teva Pharmaceutical Industries Ltd., Cardinal Health Inc., Zimmer Biomet, ZimVie Inc., Lumenis Ltd, Blueberry Therapeutics, Viatris Inc., Cardinal Health Inc., Valeant Pharmaceuticals International Inc., IMARC Group, Almirall S.A., and others.

Onychomycosis Pipeline Analysis:

The Onychomycosis pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Onychomycosis with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Onychomycosis Treatment.

*
Onychomycosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Onychomycosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Onychomycosis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Onychomycosis drugs and therapies [https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Onychomycosis Pipeline Strengths

*
The introduction of novel, inexpensive, and non-invasive diagnostic technologies have led to rapid and accurate diagnosis of onychomycosis, hence increasing the rate of diagnosis.

Onychomycosis Pipeline Market Opportunities

*
Current treatments have poor adherence and tolerability creating an opportunity for the key players to work on these areas

Scope of Onychomycosis Pipeline Drug Insight

*
Coverage: Global

*
Key Onychomycosis Companies: Moberg Pharma, Blueberry Therapeutics, Hallux, Pfizer, MediQuest Therapeutics, Polichem S.A, Repolar Ltd., Celtic Pharma, GlaxoSmithKline, Hisamitsu Pharma, Polichem S.A., Pfizer, Bausch Health, Halcygen Pharma, Meiji Seika Pharma, photonamic GmbH, Viamet, Novartis, Topica Pharma, Taro Pharma, NanoBio Crp, Hallux, Inc., Merck Sharp & Dohme, Bayer, Abeona Therapeutics, Dow Pharma, Taro Pharma, and others

*
Key Onychomycosis Therapies: MOB-015, BB2603, HSG, Tavaborole, MOB015B, P-3058, Organogel of naftifine, Amorolfine, TDT067 and Lamisil, Albaconazole, HTU-520, P-3058, AN2690, Efinaconazole, SUBA-itraconazole, ME1111, PD P 506 A, VT-1161, terbinafine, Luliconazole, NVXT topical, NB-002, HTS-519, SCH 56592, Bifonazole cream 1%, EcoNail Trademark , IDP-108, Itraconazole, and others

*
Onychomycosis Therapeutic Assessment: Onychomycosis current marketed and Onychomycosis emerging therapies

*
Onychomycosis Market Dynamics: Onychomycosis market drivers and Onychomycosis market barriers

Request for Sample PDF Report for Onychomycosis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/onychomycosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Onychomycosis Report Introduction

2. Onychomycosis Executive Summary

3. Onychomycosis Overview

4. Onychomycosis- Analytical Perspective In-depth Commercial Assessment

5. Onychomycosis Pipeline Therapeutics

6. Onychomycosis Late Stage Products (Phase II/III)

7. Onychomycosis Mid Stage Products (Phase II)

8. Onychomycosis Early Stage Products (Phase I)

9. Onychomycosis Preclinical Stage Products

10. Onychomycosis Therapeutics Assessment

11. Onychomycosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Onychomycosis Key Companies

14. Onychomycosis Key Products

15. Onychomycosis Unmet Needs

16 . Onychomycosis Market Drivers and Barriers

17. Onychomycosis Future Perspectives and Conclusion

18. Onychomycosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=onychomycosis-pipeline-trends-2024-clinical-trials-therapeutic-innovations-and-clinical-trials-by-delveinsight-blueberry-therapeutics-hallux-pfizer-bausch-health-moberg-pharma-sato-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Onychomycosis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Clinical Trials By DelveInsight | Blueberry Therapeutics, Hallux, Pfizer, Bausch Health, Moberg Pharma, Sato Pharma here

News-ID: 3574992 • Views:

More Releases from ABNewswire

Matthew Rolnick Launches 'Professional Relationship Building for Success' to Elevate Interpersonal Skills
Matthew Rolnick Launches 'Professional Relationship Building for Success' to Ele …
Matthew Rolnick's new course, "Professional Relationship Building for Success," enhances interpersonal and networking skills. Leveraging his experience as SVP at Hulk Hogan's beer and former VP at Yaymaker, the course equips participants with essential communication and relationship management techniques. It covers interpersonal communication, emotional intelligence, conflict resolution, and networking strategies. Matthew Rolnick, the Senior Vice President of Partnerships & Events for Hulk Hogan's "Real American Beer" and former Vice President of
Matthew Rolnick Debuts 'Professional Relationship Building for Success' to Transform Interpersonal Dynamics
Matthew Rolnick Debuts 'Professional Relationship Building for Success' to Trans …
Matthew Rolnick's "Professional Relationship Building for Success" course hones interpersonal skills for professional and personal growth. Leveraging his expertise from high-profile roles and interactions with influencers, Rolnick's program covers essential communication, emotional intelligence, conflict resolution, and networking. It's designed for impactful relationship management, featuring practical exercises and insights based on real-world experiences. Matthew Rolnick, the Senior Vice President of Partnerships & Events for Hulk Hogan's "Real American Beer" and an established
Redefine Elegance with ZEELOOL's
Redefine Elegance with ZEELOOL's "Girl with the Pearl Glasses"
ZEELOOL is thrilled to unveil "The Girl with the Pearl Glasses" Featured Event, inviting customers to discover styles that celebrate their individuality. This special showcase highlights our latest collection of on-trend eyewear, underscoring our dedication to quality and elegance. Eyewear That Speaks to the Heart Pink Frames Glasses: Like the bright smile of a girl in a painting, each blink unveils a canvas of youthful vitality, immersing you in a dreamlike state. Black
The Blueprint for Success: Matthew Rolnick's Comprehensive Guide to Advanced Relationship Management
The Blueprint for Success: Matthew Rolnick's Comprehensive Guide to Advanced Rel …
Matthew Rolnick's course, "Professional Relationship Building for Success," leverages his experience as SVP for Hulk Hogan's "Real American Beer" and former VP at Yaymaker to teach advanced relationship management. The course, enriched with Rolnick's interactions with figures like Fran Drescher and Mike Tyson, offers a comprehensive toolkit for effective communication, emotional intelligence, conflict resolution, and networking. In an era where forging strong connections is paramount, Matthew Rolnick's latest course, "Professional Relationship

All 5 Releases


More Releases for Onychomycosis

Dermatophytic Onychomycosis Therapeutics (DOT) Market
Market growth is primarily driven by factors such as increase in the prevalence of fungal toe nail infections in the U.S. and Canada, and rising per capita healthcare expenditure across the globe. Easy application of nail paints is also expected to drive demand for dermatophytic onychomycosis drugs. However, adverse effects associated with anti-fungal drugs and lack of awareness about dermatophytic onychomycosis in Asia Pacific, Middle East and Africa, and Latin
Onychomycosis Market Analysis with Research Report 2020
"Global Onychomycosis Market Report 2020-2026" helps the clients to take business decisions and to understand strategies of major players in the industry. The report also calls for market - driven results deriving feasibility studies for client needs. Marketinsightsreports ensures qualified and verifiable aspects of market data operating in the real- time scenario. The analytical studies are conducted ensuring client needs with a thorough understanding of market capacities in the real-
Global Onychomycosis (Tinea Unguium) Drug Market
Onychomycosis (Tinea Unguium) Drug Market Forecast 2020-2026 The Global Onychomycosis (Tinea Unguium) Drug Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes
Dermatophytic Onychomycosis Market Growth Analysis 2021
Persistence Market Research (PMR) delivers key insights on The Global Dermatophytic Onychomycosis Therapeutics Market in its latest report titled “Global Market Study on Dermatophytic Onychomycosis Therapeutics (DOT): North America Expected to Account for Maximum Market Share by 2021”. The global dermatophytic onychomycosis therapeutics market is anticipated to expand at a healthy CAGR during the forecast period. By product type, the market is segmented into Nail paint and tablet, which is again
Global Dermatophytic Onychomycosis Market Growth Analysis 2021
Persistence Market Research (PMR) delivers key insights on The Global Dermatophytic Onychomycosis Therapeutics Market in its latest report titled “Global Market Study on Dermatophytic Onychomycosis Therapeutics (DOT): North America Expected to Account for Maximum Market Share by 2021”. The global dermatophytic onychomycosis therapeutics market is anticipated to expand at a healthy CAGR during the forecast period. By product type, the market is segmented into Nail paint and tablet, which is again
Dermatophytic Onychomycosis Therapeutics Market: Global Market Intelligence
Dermatophytic onychomycosis also referred to as ringworm of the nail is one of the most common fungal infections of the nails. This infection results in the change in appearance of the nails such as, increased opaqueness and whitening along with increased thickening and fragility. Tinea unguium specifically describes the dermatophytic invasion of the nail plates and is the most common in cases when an artificial nail is applied as the